Singapore, Aug. 28 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves’ Disease Inadequately Controlled With Antithyroid Drugs'. The following are the other relevant details related to the trial:
Therapeutic Area: Endocrinology & Metabolism
Trial Centre(s):
Changi General Hospital
National University Hospital
Tan Tock Seng Hospital
Trial Status: NA
Principal Investigator(s):
Dr Soh Shui Boon
Dr Khoo Chin Meng
Dr Chen Weiliang Abel
Published by HT Digital Content Services with permission from Health Daily Digest....